Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862682 | 0.93 | KCNH2 (0.38) | KCNH2NR1I2CYP3A4SCN5AATM | |
| SCHEMBL271760 | 0.93 | KCNH2 (0.40) | KCNH2NR1I2CYP3A4SCN5AATM | |
| SCHEMBL272112 | 0.88 | KCNH2 (0.51) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL862707 | 0.86 | KCNH2 (0.36) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL863131 | 0.85 | KCNH2 (0.39) | KCNH2NR1I2CYP3A4SCN5AATM | |
| SCHEMBL278076 | 0.85 | KCNH2 (0.37) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL862950 | 0.84 | KCNH2 (0.39) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL862956 | 0.84 | KCNH2 (0.37) | KCNH2NR1I2CYP3A4SCN5AMAPK1 | |
| SCHEMBL862734 | 0.84 | KCNH2 (0.37) | KCNH2NR1I2CYP3A4SCN5AATM | |
| SCHEMBL862953 | 0.83 | KCNH2 (0.38) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280975-B1 | 7H-INDOLO[2,1-A][2]BENZAZEPINE-10-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2280975-B1 | 7H-INDOLO[2,1-A][2]BENZAZEPINE-10-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-01-01 | — | — | EP | disclosed |
| US-8133884-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133884-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133884-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2280975-A1 | 7H-INDOLOÝ2,1-A¨Ý2¨BENZAZEPINE-10-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20090280083-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-12 | — | — | US | disclosed |
| US-20090280083-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-12 | — | — | US | disclosed |
| US-20090280083-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-12 | — | — | US | disclosed |
| WO-2009137454-A1 | 7H-INDOLO[2,1-A] [2] BENZAZEPINE-10-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137454-A1 | 7H-INDOLO[2,1-A] [2] BENZAZEPINE-10-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280083-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | KCNH2 3808/4885NR1I2 189/4885CYP3A4 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.